<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89188">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02103452</url>
  </required_header>
  <id_info>
    <org_study_id>17819555</org_study_id>
    <nct_id>NCT02103452</nct_id>
  </id_info>
  <brief_title>Edessy Stem Cell Score (ESS), Endometrium, Endometrioma</brief_title>
  <official_title>Edessy STEM CELL SCORE (ESS), Endometrium, Endometrioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Azhar University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al-Azhar University</source>
  <oversight_info>
    <authority>Egypt: Ministry of Health and Population</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this study is to evaluate stem cell expression (SCE) in endometriotic (E) and non
      endometriotic ovarian and endometrial tissues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted on 40 women at Al-Azhar University Hospitals. They are divided into
      two equal groups, group 1 with ovarian endometrioma and group 2 with normal ovary. Ovarian
      and endometrial samples were evaluated by hematoxlin &amp; eosin for histopathology (HP) and of
      oct-4 for immunohistochemistry (IH) for SCE.

      Evaluation of IH parameters revealed that the most important factors for evaluating SC were
      arranged as score ( Edessy Stem Cell Score=ESS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Edessy Stem Cell Score (ESS)</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ESS
Intensity of stem cell marker:    Negative to mild =0,   Moderate =1,  Strong  =2
Percentage of stained cells:  0 =0,   0-50%= 1,   &gt;50-100% =2.
Focality :  None =0,  Focal =1,   Diffuse= 2
Distribution: None= 0, Epithelial or mesenchymal= 1, Epithelial and mesenchymal= 2.
Localization of positive stained cell: None=0, Cytoplasmic or nuclear =1, Cytoplasmic and nuclear= 2</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Endometriosis, Ovarian</condition>
  <arm_group>
    <arm_group_label>ovarian endometrioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovarian and endometrial samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal ovary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovarian and endometrial samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ovarian and endometrial samples</intervention_name>
    <description>Ovarian and endometrial samples were evaluated by hematoxlin &amp;amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE</description>
    <arm_group_label>ovarian endometrioma</arm_group_label>
    <arm_group_label>normal ovary</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 to 40 years and did not receive hormonal treatment for three month

        Exclusion Criteria:

          -  Diabetes mellitus, cardiovascular and kidney diseases, adenomyosis, Uterine fibroid
             Endometrial carcinoma  and Poly cystic ovary
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Edessy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Al-Azhar University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hala hosni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdy Olama, MD</last_name>
    <role>Study Director</role>
    <affiliation>Al-Azhar University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad A Sattar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Al-Azhar University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmad Monir, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Al-Azhar University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Al Azhar University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>March 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Azhar University</investigator_affiliation>
    <investigator_full_name>Edessy Mahmoud</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
